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Abstract: Despite recent advances in neonatal care and monitoring, asphyxia globally accounts 
for 23% of the 4 million annual deaths of newborns, and leads to hypoxic-ischemic encephalopathy 
(HIE). Occurring in five of 1000 live-born infants globally and even more in developing countries, 
HIE is a serious problem that causes death in 25%–50% of affected neonates and neurological 
disability to at least 25% of survivors. In order to prevent the damage caused by HIE, our inven-
tion provides an effective whole-body cooling of the neonates by utilizing evaporation and an 
endothermic reaction. Our device is composed of basic electronics, clay pots, sand, and urea-based 
instant cold pack powder. A larger clay pot, lined with nearly 5 cm of sand, contains a smaller pot, 
where the neonate will be placed for therapeutic treatment. When the sand is mixed with instant 
cold pack urea powder and wetted with water, the device can extract heat from inside to outside 
and maintain the inner pot at 17°C for more than 24 hours with monitoring by LED lights and 
thermistors. Using a piglet model, we confirmed that our device fits the specific parameters of 
therapeutic hypothermia, lowering the body temperature to 33.5°C with a 1°C margin of error. 
After the therapeutic hypothermia treatment, warming is regulated by adjusting the amount of 
water added and the location of baby inside the device. Our invention uniquely limits the amount 
of electricity required to power and operate the device compared with current expensive and 
high-tech devices available in the United States. Our device costs a maximum of 40 dollars and 
is simple enough to be used in neonatal intensive care units in developing countries.
Keywords: therapeutic hypothermia, evaporative cooling, hypoxic ischemic encephalopathy, 
birth asphyxia, neuroprotection
Introduction
Hypoxic ischemic encephalopathy (HIE) is a serious condition that leads to death and 
disability in neonates due to oxygen deficiency in brain. Asphyxia in neonates can be 
caused by a variety of factors, including maternal malnutrition, placental abruption, 
cord prolapse, and uterine rupture.1 On a global scale, between 50% and 89% of infants 
who suffer from severe HIE die, while many of the survivors are subject to cerebral 
or neural related disorders. Additionally, there is a 20%–37% mortality and morbid-
ity in those diagnosed with moderate HIE.2,3 Because of the morbidity and mortality 
associated with HIE, it, has become a major concern worldwide, and the high chances 
of a poor outcome for those suffering from the disease suggest a significant need for 
improved treatment. This is especially true in developing countries, where the rate of 
HIE is as high as 1.5% in newborns.4
Studies have shown that use of therapeutic hypothermia not only reduces the 
risk of death but also the possibility of long-term disability for infants who survive 
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birth asphyxia.6–11 By slowing down the formation of free 
radicals and preventing apoptosis and necrosis in neurons, 
hypothermia has been demonstrated to be a neuroprotective 
mechanism against HIE within 6 hours of birth.11,12 However, 
after 6 hours, neuroprotection is seemingly lost, which mini-
mizes the effectiveness of the treatment and could instead 
result in adverse effects.9 In addition, the infant must be at 
least 35 weeks’ gestation and weigh more than 1800 g in order 
to be considered for therapeutic hypothermia.
Therapeutic hypothermia treatments are frequently used 
to treat neonates with HIE in many developed nations. In the 
United States, the current procedure for therapeutic hypo-
thermia is whole body cooling in which the infant is placed 
on a cooling blanket with an esophageal temperature probe 
inserted into the nose for a total of 72 hours.13,14 While on 
the blanket, the baby is cooled by setting the hypothermia 
system at 33.5°C.15 Once the baby reaches a core tempera-
ture of 34°C, cooling is done in a servo manner to reach the 
target temperature of 33.5°C to avoid overcooling.9,16 Upon 
completion of the hypothermic period, a 6–10-hour rewarm-
ing process begins, during which the baby is warmed at a 
gradual rate of 0.5°C per hour or less until it reaches a core 
temperature of 36.5°C and stabilizes.11,17
Currently, therapeutic hypothermia treatments are not 
a viable standard of care in developing nations.18 Existing 
treatments are too expensive and have an electricity demand 
that surpasses the availability of power in many countries. 
Attempts to develop low-cost, low-energy therapeutic hypo-
thermia devices have been unsuccessful.19 Examples of such 
attempts have included the use of fans in South Africa, which 
lacked any method of control, and the implementation of cold 
water bottles around the baby in Uganda, which resulted in 
overshoot and an increase in side effects (ie, coagulopathy) 
and mortality.20,21
Here, we developed a low-cost, low-power therapeutic 
hypothermia device for use in developing nations. The target 
temperature during the cooling stage can be reached within 
2 hours, and the requirements for gradual rewarming can 
be met. In addition, simple control and monitoring systems 
were implemented to be appropriate for countries without 
a reliable electricity infrastructure. Utilizing this device in 
piglet models, we demonstrated the ability to mimic the 
treatments of more expensive therapies, without using the 
vast amounts of electricity required by other systems. By 
reducing the cost of therapeutic hypothermia by more than 
99% compared with existing treatments, this device is a good 




As shown in Figure 1, our device is mainly composed of two 
clay pots, sand, urea-based powder, polyethylene covering, 
styrofoam blocks, a basic microprocessor, and electronics. 
One inner pot (16 inches × 12 inches × 6 inches) is put inside 
an outer pot (17 inches × 13 inches × 9 inches). Sand and urea-
based cooling powder are mixed and placed between the outer 
and the inner pots. The inner pot with a polyethylene layer on 
top serves as a vessel in which a neonate with HIE is placed 
for hypothermia treatment. The microprocessor, thermistors, 
two AAA batteries, circuit board, and LED lights were used as 
a temperature monitoring system, which measures rectal and 
skin temperature of an infant. The total cost of our device is 
$31.50, which is 99% lower than $12,000, which is the cost 
of current advanced hypothermia devices.
For sanitary purposes, sand should be replaced every 
2 months. Urea-based cooling packet powder, which is 
applied for initial dramatic cooling, is only used one time 
per patient. When water is added to the mixture of powder 
and sand, the powder will dissolve and leak through an 
outer clay pot. For the next time use, a nurse or worker 
can simply add fresh urea powder to the existing sand in 
the device. Clay pots can be washed with soap or common 
cleaning agents and maintained for a year as long as there 
are no cracks.
Cooling
Lowering of the neonate’s core temperature is achieved 
through the use of evaporative cooling. Wet sand was placed 
between two clay pots. As shown in Figure 2, when water is 
added to the sand, the water particles slowly leave the outer 
Figure 1 Computer-aided design of the therapeutic hypothermia device.





























Figure 2 Schematic of cooling. 
Note: Temperature changes based on heat transfer, water diffusion, and air flow of the surrounding system.
clay pot through the small pores in the clay. As the water 
evaporates, heat is drawn from the inner clay pot, resulting 
in a lower temperature on the inner clay pot surface.
To understand better the heat flow in the system, a 
schematic was created (Figure 3) to model the pathway of 
temperature change. Each step was modeled with transfer 
functions. Through the use of these functions and computer 
simulations, it was determined that an inner clay pot surface 
temperature of 17°C was sufficient to lower the inner body 
temperature of the neonate to 33.5°C. Mathematical models 
indicated that the decrease in the neonate’s temperature would 
take approximately one and a half hours. In order to validate 
our model, the cooling mechanism consisting of wet sand 
between two clay pots was constructed. Water was added to 
the sand every 12 hours, and the inner pot temperature and 










TF = Transfer function
Figure 3 Model of energy flow of device.
Notes: The energy usage is transferred to either the cooling or warming method through a transfer function. The cooling or warming method transfers to a change in skin 
and rectal temperature. All of the manipulations are controlled via the control system of the device.
Warming
A maximum rate of warming of 0.5°C was required in order 
to avoid health risks associated with rapid rewarming.23,24 
Therefore, controlled passive warming was used to reduce 
the possibility of overshoot in warming. Passive warm-
ing allows the rate of temperature increase to occur more 
gradually, and also reduces the amount of energy required 
to operate the device.
In order to initiate warming, water is no longer added to 
the sand. This allows passive warming to occur more  readily. 
Passive warming is controlled by raising and lowering the neo-
nate out of and into the device. In order to raise the neonate’s 
temperature, the neonate is lifted, and a small block is placed 
underneath the baby inside the inner pot. Raising the neonate 
lifts it from the cool surface of the clay, allowing the neonate 
to undergo passive warming. Additional blocks can be added 
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inside the inner pot to increase the warming rate further. On the 
other hand, to slow down the rate of temperature increase or 
to maintain a stable cool temperature, blocks can be removed 
to lower the neonate back to the inner pot.  Therefore, lower-
ing or raising the neonate from the inner pot using the blocks 
allows us to utilize the temperature gradient of the inner pot 
to regulate the neonate’s core body temperature.
Passive warming might not be sufficient for warming a 
neonate. In this case, an active warming process is required. 
A simple and cost-effective way to implement active warm-
ing is via Kangaroo Mother Care (KMC).25 KMC is a 
technique promoted by the World Health Organization in 
which the neonate is held close to the chest of the mother or 
an attending nurse to allow excessive heat to transfer from 
the caretaker to the neonate. Should the neonate receiving 
therapeutic hypothermia treatment require a large increase in 
temperature, KMC will be applied to the newborn.
Control and monitoring system
The control system functions primarily through a peripheral 
interface microcontroller and two types of indicators, ie, 
green and yellow status LED lights (Figure 4). The microcon-
troller is programmed in conjunction with an individualized 
circuit containing thermistors to provide temperature feed-
back and to help achieve the specific temperature ranges that 
the neonate must be kept in during the cooling and warming 
processes. The green LED light will indicate that the baby’s 
core temperature is increasing at a maximum rate of 0.5°C 
per hour, while the yellow LED light means that the baby’s 
core temperature is either falling too low or rising too high 
(Figure 4). In addition, there are three supplemental LED 
lights on the side of the outer pot corresponding to three dif-
ferent heights at which the baby may be elevated or lowered 
(Figure 1). For example, if the baby is cooled too fast, the 
top LED light will turn on to indicate that the baby needs to 
be elevated to the maximum height to reduce cooling. On 
the other hand, if the baby is being warmed at a rate faster 
than 0.5°C per hour, then the middle or the lowest LED 
light will be turned on to alert a nurse to lower the baby for 
effective treatment to continue. Our control system, which 
many developing world devices currently lack, is simple and 
elegant yet requires minimal input from a nurse.26
Validation of device through animal 
experimentation
To test the more practical efficacy of our device, three piglets 
(n = 3; 2–10 days old; 1800 ± 400 g), were used in our proof-
of-concept experiment with the approval of Johns Hopkins 
Animal Care and Use Committee (Protocol SW11M475) 
and guidance from staff in the pediatric critical care unit 
laboratory and the neonatal neurointensive care nursery at 
Johns Hopkins University School of Medicine. Piglets were 
used as a model for neonates because the stages of neuronal 
development are similar to those of a neonate. Piglets were 
anesthetized by inhalation of 5% isoflurane in a 70/30 nitrous 
oxide/oxygen mixture by face mask. A tracheotomy was per-
formed, and the lungs were mechanically ventilated with 1.5% 




Digital output from microprocessor (5V)




Figure 4 Digital output of the control system.
Notes: The skin and rectal thermometers are placed in series. Recordings from these probes result in changes in the respective LED light.
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temperature probe was placed. Piglets underwent aseptic sur-
gery for placement of sterile catheters into the femoral artery 
and vein through an incision in the groin. A solution of 5% 
dextrose and 0.45% saline was infused at a maintenance rate 
of 4 mL/kg/hour. Pharmaceutical grade fentanyl was infused 
intravenously at a rate of 20 mg/kg + 20 µg/kg/hour. Pharma-
ceutical grade pancuronium was administered intravenously 
at a rate of 0.2 mg/kg + 0.2 mg/kg/hour to facilitate electro-
cauterization of the muscle layers and to prevent shivering 
with hypothermia and rewarming. The isoflurane concentra-
tion was increased, additional fentanyl boluses of 20 µg/kg 
were administered, and the fentanyl infusion was increased 
for animal comfort if the animal’s heart rate exceeded 200 
beats per minute without any other apparent cause (such as 
hypoventilation) or if blood pressure or heart rate increased by 
10% or more during surgery (a normal heart rate for a piglet 
is approximately 140–200 beats per minute).
Throughout testing on the piglets, temperature was 
checked at least every 10 minutes. To set up the device, sand 
and half a packet of urea-based cooling powder were mixed 
and placed in between the two pots. To initiate cooling, 
600 mL of tap water (24°C–39°C) was added to the sand and 
urea-based powder layer, with care taken to avoid spilling 
water into the inner pot. The piglet was cooled until it reached 
34°C, at which point it was elevated fully and a blanket was 
placed on top for passive warming. Once every half hour, 
a heating blanket was placed on the piglet for 10 minutes in 
order to mimic KMC. It was found that 10 minutes of heating 
allowed the temperature of the piglet to increase at the correct 
rate. After warming for 10 minutes with the heating blanket, 
the piglet was placed back in the clay pot. Elevation was 
changed in order to maintain the new temperature achieved 
with the heating blanket. Even while the piglet was elevated, 
an inner pot temperature of 17°C–19°C was maintained. If the 
pot started to warm, more water was added to the sand.
Temperature monitoring
Figure 4 shows a diagram of the control system circuit. The 
microprocessor uses a temperature reading from a rectal 
monitoring sensor to determine which LED light to turn on. 
A green LED light is turned on if the rectal temperature is 
within 33.5°C  ± 1°C during cooling, while a yellow LED is 
turned on to warn the nurse that the rectal temperature is not 
within the desired temperature range.27 A skin monitoring 
sensor is used as an additional safeguard to prevent any 
drastic change in temperature and dangers caused by a failure 
of rectal monitoring. The skin sensor is placed on a patient’s 
abdomen to make sure that the neonate’s skin temperature is 
not too low or too high. The same indicating LEDs are used 
to indicate temperature variability to health care providers.
Results
Cooling
By placing wet sand between two clay pots, adding water to 
the sand, and measuring room and inner pot  temperatures, 
the effectiveness of cooling was determined. Figure 5 
 demonstrates that the inner pot surface temperature was 
able to reach 17°C within one hour and 30 minutes, which is 
the target  temperature required to cool the neonate down to 
33.5°C (Supplementary Figure 1 and Supplementary Table 1). 
In addition, the device maintained this temperature without 
much variability, even with changes in room temperature, for 
over 24 hours, at which point the experiment was stopped.
Animal procedures
With the first piglet subject, only the ability to cool piglets was 
tested. It was found that the first piglet reached the target rectal 
temperature in one hour and 45 minutes, approximately match-
ing the mathematical modeling predictions. However, there 
was an overshoot in cooling, indicating that passive warming is 
required to prevent overcooling (Figure 6A). The second piglet 
was used to test elevation as a passive warming method. The 
target temperature was reached in about 25 minutes. However, 
the piglet was also underweight. Temperature stabilized at 
around 30.4°C once passive warming had been started, and this 
temperature was maintained for over 3 hours (Figure 6B).
During the third piglet test, passive warming was started 
early to prevent the overshoot seen in previous trials. The piglet 
reached the target temperature of 33.5°C around 45 minutes and 
there was no overshoot in the cooling. Although it was not pos-
sible to test KMC on the piglet due to the animal protocol, we 
calculated the amount of heat flow required to simulate KMC 
(Supplementary Figure 2). When the simulation was tested with 
a heating blanket, it was found that the core temperature was 
kept constant at the warmer temperature after the application 
of KMC for 50 minutes. Therefore, the results satisfied our 
warming constraint of 0.5°C per hour (Figure 6C).
Discussion
We have designed a low-cost and low-energy therapeutic 
hypothermia device that is able to perform effective whole 
body cooling in a piglet model. The treatment performed 
is both accurate and precise, and follows the guidelines set 
by existing technologies. The results demonstrate that the 
target temperatures were reached within the first 2 hours 
after starting treatment, which is well within the acceptable 




Cost-effective hypothermia for hypoxic ischemic encephalopathy



































1 hr 20 min
2 hr



















Figure 5 Verification of inner pot temperature. Utilizing modeling techniques, a temperature of 17°C was established as being capable of cooling the neonate to 33.5°C 


































































Figure 6 Piglet model results. (A) Demonstrates the rapid cooling of the piglet within the modeling parameters. However, because there was overshoot, passive warming 
was required during the cooling process. (B) Demonstrates sustained temperature for over 3 hours. (C) Demonstrates effective warming rate of 0.5°C per hour.
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time frame of 6 hours. This temperature was maintained in 
the live models for up to 3 hours, with no indication that 
there would be any change over longer periods of times. 
Variation in the temperature was controlled within a 1°C 
margin of error. Additionally, the device was able to rewarm 
the baby at the required rate of 0.5°C per hour.
In our study, there was variability in the amount of time it 
took to cool the piglet down. This variability can be attributed 
to the variation in mass of each piglet. Because the masses 
were highly variable, it is likely that this played a role in the 
amount of time it took to cool down the piglets. In addition, 
because cooling down the neonate quickly is important, a 
urea-based cold pack was mixed in with the sand during 
the second and third trials in order to speed up the cooling 
process. This did not affect the final temperatures, but did 
decrease the time taken to reach 17°C (Figure 6C). The 
efficiency of cooling was found to not be affected by the 
surrounding ambient temperature, because the ambient tem-
perature did not significantly affect the rate of evaporation 
(Figure 5D). In addition, the temperature of the water added 
to the sand did not affect the final temperature that the 
pot reached, and had little impact on the amount of time 
the device took to reach that temperature (Supplementary 
Table 2). However, humidity should be tested for its effects 
on the cooling aspect of the device.
We used isoflurane as an anesthetic as an additional precau-
tion in preventing harm to the piglets. Nitrous oxide was added 
to prevent animal discomfort. For future studies, the device 
will be tested with a more clinically relevant sedation method, 
such as opiate infusion, in order to more closely mimic what 
would be found in the clinical setting. Paralysis was initiated 
in order to prevent the piglets from shivering by lowering the 
thermoregulatory set point. This will prevent resistance to the 
temperature changes that therapeutic hypothermia treatment 
intends to achieve. A piglet experiment with intermittent 
paralysis or without paralysis will also be performed.
Unlike many other techniques of inducing neonatal 
 hypothermia, our device makes use of whole body  cooling. 
When only the head is cooled, a temperature gradient 
forms and the temperature of the neonate’s brain becomes 
hard to measure noninvasively, resulting in inaccurate 
 measurements of brain temperature.28 This makes therapeutic 
hypothermia treatment less efficient, and can lead to adverse 
events.  However, with whole body cooling, the entire body 
 temperature of the neonate is lowered. This has two benefits. 
First, it reduces the presence of a temperature gradient in 
the brain. In addition, because the whole body is cooled at the 
same rate, it is easier to measure internal body temperature 
by rectal monitoring, which gives an accurate depiction of 
the temperature in the brain.29
To ensure that the device is safe for use with neonates, 
biocompatibility of the materials was analyzed. Clay is 
biocompatible in neonates. Having the neonates in a moist 
environment does increase the risk of infection. Therefore, 
care must be taken to avoid spilling any water into the clay 
pots, and to make sure that none of the sand leaves the gap 
between the two pots. Any coverings placed over or on the 
device to prevent cracking will be made of polyethylene, 
which is safe for use around neonates. A significant concern 
is that the pots might crack during use, and that this could 
harm a neonate. Therefore, increasing pot thickness is being 
analyzed as a possible method to prevent fractures.
Warming was achieved through a combination of passive 
and active techniques. The prevention of further cooling and 
the ability to maintain specific temperatures was demonstrated 
with the passive technique of raising and lowering the neonate. 
This allowed for the control required to raise the temperature 
at a maximum rate of 0.5°C per hour. Active warming was 
used to raise the temperature when passive warming was 
not sufficient. In the animal experiments, active warming 
was performed using a heated blanket. However, in clinical 
studies, this warming should be provided using KMC. 
Because there are likely to be differences between the method 
used for testing and the KMC technique, KMC should be 
studied further in order to ensure that the same degree of 
controllability exists with KMC as with the heated blanket.
The monitoring and control system met the required 
precision of a 1°C margin of error, and allowed for clinically 
acceptable monitoring of temperature. The LED lights 
indicating overheating and overcooling worked, and are a 
simple method for health care workers to assess the current 
status of the neonate placed in the device. Because overshoot 
can increase the risk of mortality and morbidity, it is essential 
that the control and monitoring system be proficient. Currently, 
the design requires the presence of a nurse or attending health 
care worker in order for changes in temperature to be made. 
Automation of the system would be ideal; however, this 
poses a significant challenge due to electricity requirements. 
Therefore, making the control system as self-sustained and 
the device as inclusive as possible is important in order to 
facilitate the task of treating neonates with this device.
One of the major problems with existing devices is cost. 
By using materials readily available at low cost in developing 
countries, a final cost of about $30 is predicted for this device 
(Supplementary Table 3). This makes our device a viable 
product for the treatment of HIE in the developing world.
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In conclusion, this study demonstrates the ability of our 
device to cool down a piglet and then rewarm it, following the 
guidelines set by the standard of care that exists for technolo-
gies in developed countries. This device has the potential to 
be a valuable treatment to reduce the impact of HIE in the 
developing world. Nevertheless, we believe that this device 
should not be introduced into clinical practice in any country 
without data from carefully designed prospective trials that 
have been approved by regional ethical or clinical research 
committees and the US Food and Drug Administration for 
trials in the United States, given the potential of overcooling 
to cause increased morbidity in this fragile group of neonates, 
as has happened before in a previous trial.20
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Supplementary materials
Figure S1 Demonstrating the cooling requirements.
Note: These equations demonstrate the amount of energy required to cool a neonate given metabolic generation and surface area approximations.
Average food calorie intakefor neonate calories per day
Genera
= 400
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To cool a neonate from 37ºC to 35.5ºC
= 3500 J/kg ºC × 2.5 kg × 3.5ºC
= 30625 Joules
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Table S3 Current cost of device
Component Cost Supplier
2 Ceramic pots $4.00 Indian Pot Suppliers
Sand $0.61 Logistic Chemisols
Scissor stand $10 Brilife (Shanghai) International Trading Co, Ltd
Microprocessor with analog to digital convertor $10.39 Shenzhen Shijibaike Electronics Co, Ltd
Circuit board $0.50 Shenzhen Hongmy Precision Circuit Co, Ltd
Medical grade thermisters $2.00 Zhaoqing Exsense Electronics Technology Co, Ltd
Cotton blanket $1.40 Shanghai Baby Products
5 hours of semi-skilled labor (soldering, sewing, wiring, etc) $0.45 Pooja Group
Cotton fabric $1.97 Crafty Cuts
LLDPE coating $0.03 Fortune Plastics
Teflon coating $0.25 Suzhou Brisun Trading Co
Total cost of device $31.60
Table S1 Simulation data of conductive cooling using the heat 
flux equations in Supplementary Figure 1
Conductive cooling  
temp (°C)




17 33.5 1 hr 20 min
19 33.5 2 hr
23 35 5 hr 30 min
Note: It takes about one hour and 20 minutes to reach 33.5 of neonate’s body 
temperature at 17°C conductive cooling.
Table S2 Modeling varying initial temperatures of water with 
final temperature of inner pot






Notes: With the help of Ammonium Nitrate, the water temperature can be maintained 
between 13°C–17°C when the initial water temperature varies from 24°C–39°C.
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KMC warming rate = 0.13°C/min (no skin to core temp correlation)
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